spartalizumab + LAG525 + canakinumab

This drug is a **combination of three monoclonal antibodies**: spartalizumab (anti-PD-1), LAG525 (anti-LAG-3), and canakinumab (anti-interleukin-1β). Spartalizumab is a humanized IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), functioning as a checkpoint inhibitor to enhance T-cell mediated anti-tumor responses[1][5]. LAG525 is an IgG4 monoclonal antibody that blocks lymphocyte activation gene 3 (LAG-3), another immune checkpoint, aiming to further improve T-cell activation and antitumor immunity. Canakinumab is a recombinant human monoclonal antibody that specifically binds interleukin-1β and neutralizes its inflammatory activity, indicated for inflammatory disorders and also explored in cancer immunotherapy settings[2][4][6]. This combination is under investigation for advanced solid tumors, particularly in cancers resistant to immune checkpoint monotherapy; the rationale is to target multiple immune pathways (PD-1 and LAG-3) and modulate the tumor microenvironment (IL-1β inhibition)[1][5].

Other names

spartalizumab + LAG525 + canakinumab